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Background: Children with advanced heart failure, particularly those with 
elevated pulmonary vascular resistance, pose a difficult management 
problem because the normal donor right ventricle cannot cope with the 
high pulmonary resistance and because of the relative shortage of donor 
organs of an appropriate size for this age group. Methods: In an attempt o 
address these issues and evaluate the role of heterotopic transplantation in 
this context, we operated on 12 children, six boys and six girls, in the period 
between January 1. 1991. and March 31, 1996. Their ages ranged from 1! 
months to 15.2 years (mean 81.6 -+ 62.8 months) and their mean weight was 
23.3 kg (range 7.6 to 56.8 kg). Eight patients (66.6%) had significant 
elevation of pulmonary artery pressure (pulmonary artery systolic pres- 
sure = 66 + 9.4 mm Hg, mean transpulmonary gradient = 22.3 - 3.4 mm 
Hg). In all patients the donor pulmonary artery was anastomosed to the 
recipient right atrium without the use of any prosthetic material. Ischemic 
times varied between 135 and 255 minutes (mean 182.1 - 30.7 minutes). 
The immunosuppression regimen included cyclosporine and azathioprine. 
Steroids were not routinely used. Results: One patient died in the hospital 
of acute rejection on postoperative day 16. Three patients had lobe collapse 
within 1 week and all were treated successfully. Two late deaths (18.2%) 
occurred as a result of cardiac rejection 3 months and 2 years after the 
operations. Nine survivors (75%) are alive, active, and growing normally at 
a mean follow-up of 2.2 years ~range 11 months to 4.75 years). Repeated 
cardiac catheterization performed in seven patients with preoperative 
pulmonary hypertension showed a slow progressive drop in mean pulmo. 
nary artery pressure. No significant change was observed in the function of 
the recipient hearts. Conclusion: We conclude that heterotopic heart 
transplantation is feasible for a selected group of children with good 
medium-term results, notably regression of pulmonary artery pressure, 
normal growth, and lack of long-term chest complications. (J Thorac 
Cardiovasc Surg 1997;113:1042-9) 
rthotopic heart transplantation is an accepted 
and effective method for the management of 
end-stage congestive heart failure. On the contrary, 
the use of heterotopic heart transplantation is still 
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controversial, with only a few reports, particularly in 
pediatric patients) -s
Children with advanced heart failure, particularly 
those with elevated pulmonary vascular resistance 
(PVR), pose a difficult management problem because 
of the scarcity of suitable organ donors in this age 
group and the high rate of detrimental right heart 
failure in the presence of elevated PVR. Waiting time 
for a suitable orthotopic transplant, especially when a 
"domino" heart is required, is often excessive and 
associated with a significant mortality in this age 
group? Heart-lung transplantation may be an option 
in patients with elevated PVR, although recent evi- 
dence that obliterative bronchiolitis is prevalent in the 
pediatric population has presently reduced the enthu- 
siasm for the procedure in this subgroup. TM 
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Fig. 1. Matching of donor to recipient body weight. The line of unity represents 1:1 size matching. Three 
donors were oversized, one significantly. The remainder of the donors were undersized. DRWR, 
Donor/recipient weight ratio. 
Table I. Recipient age and weight at operation, recipient hemodynamic data before transplantation, donor age 
and weight, donor~recipient weight match, hemodynamic result after transplantation, and outcome 
Recipient data Donor data Late hemodynamic result 
Age Weight SysPAP TPG Age Weight SysPAP TPG 
Case (too) (kg) Diagnosis Onto Hg) (ram Hg) (too) (kg) DRWr (mm Hg) (mm Hg) Outcome 
1 16 7.6 RCM 70 17 11 10.3 1.36 38 12 Alive 
2 164 30 RCM 60 23 60 18 0.6 22 9 Alive 
3 37 12.1 DCM 80 22 11 10 0.83 26 5 Alive 
4 27 11 DCM * * 24 12 1.09 * * Dead (early) 
5 114 44 DCM 32 8 108 25 0.57 * * Alive 
6 146 40.8 DCM 43 5 132 23 0.56 * * Dead (late) 
7 46 12.5 RCM 64 22 21 10 0.8 32 8 Alive 
8 11 9.4 DCM 50 23 5 6 0.64 20 6 Alive 
9 183 56.8 DCM 60 30 108 30 0.53 20 6 Alive 
20 53 12.9 RCM 79 22 54 21 1.63 34 12 Alive 
~1 160 31.4 DCM 65 20 120 30 0.96 * * Dead (late) 
12 26 10.7 DCM 26 6 24 10 0.93 * * Alive 
SysPAP, Systolic pulmonary artery pressure; TPG, transpuImonary gradient; RCM, 
donor/recipient weight ratio. 
*Data not available. 
restrictive cardiomyopathy; DCM, dilated cardiomyopathy; DRWr, 
Although heterotopic  heart  t ransplantat ion in 
chi ldren has general ly been considered impract ical  
because of  the small size of the recipient thoracic 
cavity, 8 the procedure  might be a valuable alterna- 
tive in selected cases. In an at tempt to clarify the 
possible role of heterotopic  heart  t ransplantat ion i  
children, we have retrospectively analyzed the expe- 
r ience developed at a single institution with a large 
transplant volume. 
Methods 
Since the beginning of the transplant program at 
Harefield in 1980 until March 1996, 1278 cardiac trans- 
plantations have been performed. Of these, 104 were 
heterotopic heart transplantations, representing 8.1% of 
the total experience. Since January 1991, 12 children, six 
boys and six girls, underwent heterotopic heart transplan- 
tation (11.6% of all recipients of heterotopic hearts). 
Their ages ranged from 11 months to 15.2 years (mean 
81.6 _+ 62.8 months) and their mean weight was 23.3 kg 
(range 7.6 to 56.8 kg). The age and weight of the donors 
were 56.5 months (range 11 months to 10 years) and 17.1 
kg (range 6 to 30), respectively (Table I). Donor/recipient 
weight ratio ranged between 0.53 and 1.63, mean 0.87 
(Fig. 1). Eight patients had dilated cardiomyopathy and 
four, restrictive cardiomyopathy. All children had severe 
congestive heart failure while receiving maximal medical 
therapy. Indications for heterotopic heart transplantation 
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Fig. 2. The completed heterotopic heart transplant. The 
donor SVC was ligated in patients younger than 5 years 
old. Note the anastomosis of the donor pulmonary artery 
to the recipient right atrium. 
included a significantly undersized onor (42%) and the 
presence of pulmonary hypertension i a recipient with 
PVR between 4 and 7 Wood units or a transpulmonary 
gradient above 10 mm Hg (eight patients: 66.6%; pulmo- 
nary artery systolic pressure = 66 + 9.4 mm Hg, mean 
transpulmonary gradient = 22.3 -+ 3.4) (Table I). In two 
patients (16.6%) younger than 2 years old, heterotopic 
heart transplantation was performed to allow for possible 
recovery of the recipient heart. Indications for heterotopic 
heart transplantation verlapped in some cases. 
The total mean ischemic time for the donor organ was 
182.1 -+ 30.7 minutes, with a range of 135 to 255 minutes. 
Mean cardiopulmonary b pass time was 85 -+ 32 minutes 
(range 57 to 162 minutes). 
Surgical technique. Through a median sternotomy the 
right pleural space was opened wide and the pericardium 
was released from the diaphragm down to the inferior 
vena cava. Aortic and bicaval venous cannulation was 
used in all cases. The donor heart was harvested with a 
long segment of the superior vena cava (SVC) and the 
transverse aortic arch. The donor inferior vena cava was 
oversewn and the left atrium opened wide by connecting 
the orifice of the four pulmonary veins. For implantation 
after establishment of cardiopulmonary b pass, the native 
heart was fibrillated and the left ventricle vented through 
a stab wound in the apex. The recipient intraatrial groove 
was dissected in a fashion similar to the standard mitral 
valve approach. The donor heart was then placed in the 
right pleural cavity with the apex to the right, and the left 
atrium-left atrium anastomosis was constructed with run- 
ning polypropylene suture. In five patients (42%), all 
younger than 5 years old, the donor SVC was ligated; in 
the remaining seven (58%) it was anastomosed to the 
recipient SVC in an end-to-side fashion and as high as 
possible on the native SVC, because a high anastomosis 
Fig. 3. Representative chest roentgenogram after heter- 
otopic heart transplantation i  an infant. 
seems to facilitate subsequent donor heart biopsy. The 
aortic anastomosis was then constructed end to side on 
the recipient ascending aorta. The recipient heart was 
continuously perfused throughout the procedure. In all 
cases the donor pulmonary artery was connected to the 
recipient right atrium according to the original hetero- 
topic technique first described by Barnard and Losman, 12 
in which the donor heart provides assistance to the left 
side of the heart only (Fig. 2). Temporary epicardial 
atrioventricular pacing wires for both donor and recipient 
hearts and chest tube drainage of the mediastinum and 
right side of the chest were routinely placed before 
closure. A typical chest roentgenogram of a patient after 
the procedure is shown in Fig. 3. 
No major problems were related to the limited intratho- 
racic space except in one patient whose sternum was 
stented open for 72 hours after the operation to improve 
cardiac output. 
Immunosuppressive therapy. Immunosuppression i  
the early postoperative p riod consisted of cyclosporine A 
and azathioprine with minimal or no steroid use. 
Clinical and echocardiographic criteria were used to mon- 
itor for acute cardiac rejection. Endomyocardial biopsy was 
used to confirm acute rejection in selected patients. 
Follow-up. Routine monitoring was used in the inten- 
sive care unit in the immediate postoperative period. 
Serial echocardiograms were used to evaluate donor and 
recipient ventricular performance. In the early postoper- 
ative period three patients (25%) underwent successful 
temporary paced linkage of donor and recipient hearts to 
achieve coordinated contraction of the two organs, with 
significant hemodynamic improvement. 13 
After discharge, patients were evaluated in the trans, 
plant clinic at regular intervals. Cardiac catheterization 
was performed yearly in most patients. 
Statistics. Statistical analysis was performed with the 
use of commercially available software (Arcus Prostat 
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Fig. 4. Actuarial survival curve of pediatric heterotopic transplant recipients. One- and 5-year actuarial 
survivals were 83% and 66%, respectively. Numbers of patients at risk at each time point are shown in 
parentheses. 
version 3) (Medical Computing, West Lanes, United 
Kingdom). All data are given as mean ± standard evia- 
tion unless otherwise xpressed. 
Actuarial survival curves were calculated according to 
the method of Kaplan and Meier. 14 Postoperative data 
were compared with the baseline by means of a one-way 
analysis of variance. All p values less than 0.05 were 
accepted as significant. 
Results 
Survival. One patient died in the hospital of 
clinically suspected acute rejection on postoperative 
day 16 despite maximized immunosuppressive tr at- 
ment. This child was not considered for retransplan- 
tation because of multiorgan dysfunction. A 13-year- 
old boy with dilated cardiomyopathy and pulmonary 
hypertension died suddenly at home 4 months after 
the operation after repeated episodes of biopsy-proved 
acute rejection. A 12-year-old girl died of severe heart 
failure in another institution 2 years after transplanta- 
tion after progressive chronic cardiac rejection con- 
firmed by autopsy. In this patient the native heart 
tolerated the donor heart dysfunction for some time 
while the patient waited for retransplantation. Three 
patients (25%) had lobar collapse after transplanta- 
t ion-the right middle lobe, the right upper lobe, and 
both lower lobes, respectively. The first two were 
successfully managed conservatively. The third patient, 
who had also undergone sternal stenting immediately 
after the operation, required late reintubation and 
tracheostomy before being uneventfully extubated 2
weeks later. 
Within the first 3 postoperative months, an aver- 
age of 1.3 rejection episodes per patient necessitated 
intensified immunosuppressive therapy. 
Actuarial 1-year survival for the group was 83.3% 
(Fig. 4). All nine survivors are active and growing 
normally at a mean follow-up of 2.2 years (range 11 
months to 4.75 years). 
Postoperative cardiac catheterization in seven 
long-term survivors with preoperative pulmonary 
hypertension showed a significant drop in pulmo- 
nary pressure (Fig. 5 and Table I). 
Two-dimensional echocardiographic assessment 
was performed before discharge and then at 3 months, 
6 months, and every year after the operation. The 
ejection fractions and shortening fractions of the do- 
nor and recipient hearts were evaluated at regular 
intervals did not show any progressive significant dif- 
ference, with a fairly constant level of performance of 
both hearts (Fig. 6). Mean shortening fractions of the 
donor and recipient hearts at 6 months were 39.1% + 
4.5% and 14.5% _+ 12.5%, respectively. 
Postoperative volution of donor and recipient 
left ventricular mass is shown in Fig. 7. 
Discussion 
This study has shown that heterotopic heart trans- 
plantation, in a specific cohort of children, is feasible 
and gives good results in the medium term. Although 
heterotopic heart transplantation is not commonly 
applied, it continues to account for approximately 10% 
of all heart transplantations in our center. 
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Fig. 5. Postoperative r gression of mean pulmonary artery pressure. In patients with preoperative 
pulmonary hypertension, mean pulmonary artery pressure was reduced after heterotopic transplantation 
for the duration of follow-up. 
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Fig. 6. Ejection fractions (EF) of the donor and recipient hearts were stable for the duration of follow-up. 
The main indications for this procedure are (1) 
presence of fixed high PVR, (2) availability of 
undersized onor, (3) expectation of a certain de- 
gree of recipient heart recovery. 
Encouraging results in adults* and in a limited 
number of children s have led us to expand this 
program. In theory, this approach has several ad- 
vantages, which include a better use of donor or- 
gans, suitability of the procedure in the presence of 
*Khaghani A, Dyke C, Santini F, et al. Medium and long term 
results of heterotopic heart transplantation. Unpublished ata. 
high PVR, patient survival not entirely dependent 
on the donor organ, and possible recovery of the 
recipient heart. 
However, theoretical disadvantages in children 
also exist, such as lack of wider experience and 
data, technical problems related to the size of the 
thoracic cavity, and doubt about the reversibility 
of the PVR. 
Five children in our group (42%) underwent 
heterotopic heart ransplantation with a significantly 
undersized onor. One patient in this subgroup died 
of severe heart failure 2 years after transplantation, 
having had progressive chronic cardiac rejection. 
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Fig. 7. Left ventricular (LV) mass of the donor and recipient hearts did not change significantly after 
heterotopic transplantation. 
Four of these undersized pediatric donor hearts 
(80%) had previously been rejected for transplanta- 
tion by one or more other transplant centers for lack 
of size-matchable recipients (United Kingdom 
Transplant Support Service Authority, unpublished 
data). It appears therefore that heterotopic heart 
transplantation can effectively expand the organ 
donor pool, decreasing waiting time and waiting 
time mortality] 
A significant increase in mortality after conven- 
tional orthotopic transplantation asa result of high 
PVR and elevated transpulmonary gradient has 
been documented. ~5' 16 
Several options have been investigated in the past 
for this group of recipients, including the use of a 
larger donor, 17 domino heart, 18' 19 heart-lung trans- 
plantation, 2° and heterotopic heart transplantation. 3 
Domino or prepared hearts for recipients with pul- 
monary hypertension have been successfully and 
extensively used in the adult population. However, 
the pool of usable domino hearts from the pediatric 
group is limited. Therefore waiting time for a suit- 
able organ in children often becomes excessive and 
associated with significant mortality, s 
Heart-lung transplantation may be an option in 
children with elevated PVR. However, evidence of 
an increased incidence of obliterative bronchiolitis 
in this age group has reduced enthusiasm for the 
procedure.941 
Seven of eight patients with preoperative pulmo- 
nary hypertension i our series are long-term survi- 
vors. All but one underwent at least one cardiac 
catheterization between 3 and 4 years after the 
operation, which showed in all a progressive and 
significant drop in pulmonary pressure. The only 
death in this subgroup occurred suddenly 4 months 
after the operation after multiple episodes of acute 
rejection. Also in this patient cardiac catheteriza- 
tion, undergone 3 months before the operation, 
showed a drop in mean pulmonary pressure from 40 
to 16 mm Hg. 
Two children under the age of 21/2 years under- 
went heterotopic heart transplantation to allow for 
possible recovery of the recipient heart. One of 
these patients died during the early postoperative 
period. The other patient's native heart at 12 
months has shown significant improvement with a 
shortening fraction of more than 25%. 
Heterotopic heart transplantation has had little 
use in the pediatric population, being generally 
considered inadvisable because of the size limitation 
of the thoracic cavity in this group. 8 In our experi- 
ence the size of the recipient horacic avity was not 
a technical problem. The smallest patient in our 
series weighed 7.6 kg at the time of transplantation. 
However, three patients (25%) in our experience 
had perioperative and early postoperative complica- 
tions related to pulmonary compression. These 
events were treated successfully in all, with no 
recurrence of long-term chest complications. Al- 
though no other complications were observed ur- 
ing the follow-up period, the binomial upper confi- 
dence bound on zero events in 12 patients is 22%, 
and we could be missing event rates as high as 22%. 
It has been our policy in children to make a 
diagnosis of acute rejection in the early postopera- 
tive period by using noninvasive techniques. There- 
fore the donor SVC was ligated in the vast majority 
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of the patients under 5 years of age with the 
knowledge based on our previous experience that 
endomyocardial biopsies are still technically feasible 
via the recipient right a t r ium-donor  pulmonary 
artery anastomosis, if needed. 
All nine survivors (75%: mean follow-up 2.2 
years) are active children with normal social inter- 
actions and satisfactory growth patterns. 
In conclusion, we believe that heterotopic heart 
transplantation warrants consideration and further 
use in selected pediatric patients, particularly in the 
presence of secondary pulmonary hypertension, an 
undersized onor, and the expectation of a certain 
degree of recipient heart recovery. 
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Discussion 
Dr. Charles B. Huddleston (St. Louis. Mo.J. it is a 
privilege to discuss a paper from one of the greatest 
cardiothoracic units in the world. This review from 
Harefield addresses a couple of important issues in car- 
diac transplantation in children. My comments and ques- 
tions center around the indications for this procedure. For 
instance, when should heterotopic transplantation be 
used? 
You seem to be classifying two distinct groups as 
children small infants and teenagers. Calculating the 
means of some variables of the two groups as a whole 
seems a bit misleading. At any rate, without question. 
donor availability is the most critical issue in cardiac 
transplantation, and it has driven transplant surgeons 
treating adults to invade the pediatric-age donor pool for 
organs to be used in older reopients, it is not at all 
unusual for them to use a 40 kg donor in a 70 kg recipient 
with a successful outcome. This practice has had a nega- 
tive impact, however, on the availability of organs for our 
teenaged recipients. This problem has become vident in 
our own program recently at St. Louis Children's Hospi- 
tal. We have five teenagers with status I disease who have 
been in the pediatric intensive care unit at our hospital for 
more than 3 months, two of whom are now supported by 
biventricular assist devices. For a hypothetical 50 kg 
recipient, how small a donor would you use in the 
orthotopic position and how small a donor would you then 
deem acceptable in a heterotopic position? I envision 
expanding the donor pool for our teenaged recipients 
down into the pediatric age range of 5 to 10 years, where 
not many recipients are currently waiting, as an answer to 
the problem for the teenagers. 
Regarding the elevated PVR indication, all of our 
potential recipients with an elevated PVR undergo a 
rigorous evaluation in the catheterization laboratory to 
test their responsiveness to various pulmonary vasodila- 
tors and inotropic agents. With this approach we have 
performed orthotopic heart transplantations on five chil- 
dren whose initial evaluation would have excluded them 
on the basis of the standard accepted criteria. All have 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 113, Number 6 
Khaghani et al. 1 0 4 9 
survived, but some have required significant chemical 
support after transplantation, including inhaled nitric 
oxide and peripheral vasoconstrictors. Given that this 
study and others have shown a progressive fall in the PVR 
and pulmonary artery pressures over time after transplan- 
tation, it seems unlikely to me that elevated PVR resulting 
from heart failure alone would portend a poor long-term 
prognosis. What sort of pretransplantation evaluation of 
the pulmonary hemodynamics is done at Hare field? 
Finally, one of your stated indications for this approach 
is the potential recovery of native cardiac function. I agree 
that this may occasionally happen and that there are 
certain predictors of this, such as very young age. It is a 
tribute to the staff of Harefield that you have been able to 
perform this challenging procedure in such small children. 
My question is this: Have there in fact been any patients 
whose native heart function has recovered? If so, would 
you consider a transplant cardiectomy so that they would 
no longer need immunosuppressants? I would remind 
you, and I am sure this is something that you have already 
thought of, that you could then potentially use that donor 
heart again in another ecipient. 
Dr. Santini. Dr. Huddleston, thank you for your com- 
ments. Regarding the size of the donor, the smallest donor 
successfully used in our experience had a weight ratio to 
the recipient of 0.5. This was a 16-year-old recipient with 
pulmonary hypertension. Thus I would say that a donor 
who is half the weight of the recipient can still be used for 
heterotopic transplantation. However, I would not be 
happy to use the heart from a 25 kg donor for a 50 kg 
recipient in tile orthotopic position. 
oncerning the assessment of PVR in our recipients, 
all of the patients who have been studied in the 
catheterization laboratory have been given oxygen, 
isoprenaline, and nitroprusside to test pulmonary vas- 
cular reactivity. For those patients with resistant pul- 
monary hypertension, postoperative right heart dys- 
function still remains a major concern after 
conventional orthotopic heart transplantation. I do 
agree, however, that elevated PVR resulting from heart 
failure alone carries a better prognosis than PVR 
related to an Eisenmenger complex. 
Regarding the recovery of the native heart, in the 
pediatric population after heterotopic transplantation, the 
recipient heart function not only did not deteriorate but 
also showed a degree of improvement in some cases. I
think it is conceivable that later on this improvement may 
allow an eventual explantation of the donor heart. The 
possibility of using this donor heart again is an interesting 
idea that we have not tested yet. 
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